Eli Kirshner, MD
Hematology & Oncology · Westwood, NJNPI 1376627737
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,673 of the $34,296 with a category attached, or 66.1%. 45 manufacturers reported payments, led by AstraZeneca at 48.2% of the total. Reporting peaked in 2022 at $9,175 and has fallen 76.0% since, to $2,200 in 2025. Among hematology & oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $117.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- Astellas Pharma Global Development$7K
- Johnson & Johnson$3K
- Exelixis Inc.$2K
- Blueprint Medicines Corporation$2K
- Beigene, Ltd.$450
- plus $4K from 39 others
Across 207 payments — averaging $5785.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$332K
- Merck$312K
- EMD Serono, Inc.$128K
- Seagen Inc.$111K
- Eli Lilly$64K
- F. Hoffmann-la Roche AG$60K
- plus $190K from 9 others
What the payments were for
- Consulting fees$22,67366%
- Speaking & faculty fees$4,67614%
- Travel & lodging$1,9266%
- Food & beverage$4,65714%
- Education$3651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,296 in reported general payments places this provider in the 90th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 37 | $630,166 |
| CabometyxCabozantinib S-Malate | 20 | $505,746 |
| ImbruvicaIbrutinib | 30 | $468,232 |
| CalquenceAcalabrutinib Maleate | 42 | $430,967 |
| Lenalidomide | 38 | $427,452 |
| JakafiRuxolitinib Phosphate | 19 | $328,844 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $184,487 |
| TafinlarDabrafenib Mesylate | 12 | $169,922 |
| VenclextaVenetoclax | 31 | $144,738 |
| Abiraterone Acetate | 293 | $106,128 |
| XareltoRivaroxaban | 73 | $79,996 |
| EliquisApixaban | 73 | $52,084 |
| Erlotinib Hcl | 12 | $46,246 |
| Hydroxyurea | 107 | $2,749 |
| Prednisone | 328 | $1,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $16,539 | $1,061,13379 claims |
| Exelixis Inc.Cabometyx | $2,116 | $505,74620 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $354 | $468,23230 claims |
| NovartisMekinist, Tafinlar | $268 | $354,40924 claims |
| Incyte CorporationJakafi | $158 | $328,84419 claims |
| AbbVieVenclexta | $60 | $144,73831 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $126 | $106,128293 claims |
| Johnson & JohnsonXarelto | $2,968 | $79,99673 claims |
| PfizerEliquis | $97 | $52,08473 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Westwood
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
- Anthony BottiLivingston$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.